Related Experiment Video
Updated: Mar 3, 2026

Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury
Published on: February 23, 2015
The toll-like receptor 2 agonist Pam3CSK4 is neuroprotective after spinal cord injury
Nicole S Stivers1, Nicolas Pelisch1, Ben C Orem1
1Kentucky Spinal Cord Injury Research Center and Departments of Neurological Surgery, Microbiology and Immunology, Anatomical Sciences and Neurobiology, University of Louisville, Louisville, KY, USA.
Abstract:
Microglia/macrophage activation and recruitment following spinal cord injury (SCI) is associated with both detrimental and reparative functions. Stimulation of the innate immune receptor Toll-like receptor-2 (TLR2) has shown to be beneficial following SCI, and it increases axonal regeneration following optic nerve crush. However, the mechanism(s) remain unclear. As microglia express high levels of TLR2, we hypothesized that modulating the microglial response to injury using a specific TLR2 agonist, Pam3CSK4, would prevent secondary-mediated white matter degeneration following SCI. To test this hypothesis, we documented acute changes in microglia, axons, and oligodendroglia over time using two-photon excitation and an ex vivo laser-induced SCI (LiSCI) model. We utilized double transgenic mice that express GFP in either microglia or oligodendroglia, and YFP in axons, and we applied the lipophilic fluorescent dye (Nile Red) to visualize myelin. We found that treatment with Pam3CSK4 initiated one hour after injury induced a significant increase in the extent and timing of the microglial response to injury compared to vehicle controls. This enhanced response was observed 2 to 4h following SCI and was most prominent in areas closer to the ablation site. In addition, Pam3CSK4 treatment significantly reduced axonal dieback rostral and caudal to the ablation at 6h post-SCI. This protective effect of Pam3CSK4 was also mirrored when assessing secondary bystander axonal damage (i.e., axons spared by the primary injury that then succumb to secondary degeneration), and when assessing the survival of oligodendroglia. Following these imaging experiments, custom microarray analysis of the ex vivo spinal cord preparations revealed that Pam3CSK4-treatment induced an alternative (mixed M1:M2) microglial activation profile. In summary, our data suggest that by providing a second "sterile" activation signal to microglia through TLR2/TLR1 signaling, the microglial response to injury can be modulated in situ and is highly neuroprotective.
Insights
Stimulating Toll-like receptor-2 (TLR2) with Pam3CSK4 enhances microglial response after spinal cord injury (SCI), reducing axonal damage and improving oligodendroglia survival for neuroprotection.
Area of Science:
- Neuroscience
- Immunology
- Regenerative Medicine
Background:
- Microglia/macrophage activation after spinal cord injury (SCI) has dual roles, impacting both damage and repair.
- Toll-like receptor-2 (TLR2) stimulation shows promise for SCI recovery and axonal regeneration, but mechanisms are unclear.
- Microglia are key players in the inflammatory response to SCI, expressing high levels of TLR2.
Purpose of the Study:
- To investigate if modulating microglial response via a TLR2 agonist, Pam3CSK4, can prevent secondary white matter degeneration after SCI.
- To elucidate the mechanisms underlying TLR2 agonist-mediated neuroprotection in the context of SCI.
Main Methods:
- Utilized an ex vivo laser-induced SCI (LiSCI) model in double transgenic mice (GFP in microglia/oligodendroglia, YFP in axons).
- Visualized myelin using Nile Red dye and tracked acute changes in microglia, axons, and oligodendroglia using two-photon excitation microscopy.
- Administered Pam3CSK4 one hour post-injury and performed microarray analysis to assess microglial activation profiles.
Main Results:
- Pam3CSK4 treatment significantly enhanced the extent and timing of microglial response 2-4 hours post-SCI.
- Pam3CSK4 significantly reduced axonal dieback and secondary axonal damage at 6 hours post-SCI.
- Pam3CSK4 treatment improved oligodendroglia survival and induced a mixed M1:M2 microglial activation profile.
Conclusions:
- Modulating microglial activation through TLR2/TLR1 signaling with Pam3CSK4 is a viable neuroprotective strategy following SCI.
- Pam3CSK4 treatment in situ mitigates secondary degeneration and promotes neuronal and glial survival after spinal cord injury.
- Targeting TLR2 offers a promising therapeutic avenue for enhancing recovery after spinal cord injury.
More Related Videos
09:14Experimental Strategies to Bridge Large Tissue Gaps in the Injured Spinal Cord after Acute and Chronic Lesion
Published on: April 5, 2016
09:08A Neurosphere Assay to Evaluate Endogenous Neural Stem Cell Activation in a Mouse Model of Minimal Spinal Cord Injury
Published on: September 13, 2018